systemic lupus erythematosusnephritistreatmentprognosisсистемная красная волчанкинефритлечениепрогноз1.Тареева И. Е. Нефрология. М.: Медицина; 2000. 280-291.2.Тареева И. Е., Шилов Е. М., Краснова Т. Н. и др. Прогноз больных быстропрогрессирующим волчаночным нефритом при различных методах лечения. Тер. арх. 1994; 6: 4-7.3.Соловьев С. К., Насонова В. А. Современные представления об интенсивной терапии системной красной волчанки. Рус. мед. журн .2000; 6: 1195-1198.4.Cameron J. S. What is the role of long-term cytotoxic agents in treatment of lupus nephritis. J. Nephrol. 1993; 6: 172-176.5.Cameron J. S. Lupus nephritis. J. Am. Soc. Nephrol. 1999; 10: 413-424.6.Bono L., Cameron J. S., Hicks J. A. The very long-term prognosis and complications of lupus nephritis and its treatment. Quart. J. Med. 1999; 92: 211-218.7.Titmlin J. A. Lupus nephritis: novel immunosupression modalities and future directions. Semin. Nephrol. 1999; 19: 67-76.8.Pinto L. F., Senior J. M., Ceron J. A. et al. Nephropatia lupica. Acta Med. Colombiana 1992; 18:157-163.9.Серов В. В., Варшавский В. А., Куприянова Л. .А. Иммунопатология почек. М.: Медицина; 1983. 176.10.Esdaile J. M., Joseph L., McKenzie Т. et al. The pathogenesis and prognosis of lupus nephritis: information from repeat renal biopsy. Semin. Arthr. Rheum. 1993; 23: 135-148.11.Esdaile J. M. Current role of renal biopsy in «patients with SLE. Baillieres Clin. Rheumatol. 1998; 12: 433-448.12.Nossent H. C., Henzen-Logmans S. C., Vroom Т. М. et al. Contribution of renal biopsy data in predicting outcome in lupus nephritis. Arthr. and Rheum. 1990; 33: 970-977.13.Ferluga D., Jerse M., Virjak A. et al. Correlation among WHO classes, histomorphologic patterns of glomerulonephritis and glomerular immune deposits in SLE. Wien. Klin. Wschr. 2000; 112: 629-701.14.Kater L., Derksen R. H., Hene R. J. Treatment of systemic lupus erythematosus: which options do we have for therapy regimens. Rheumatol. Int. 1991; 11: 137-140.15.Derksen R. H., Hene R. J., Kater L. The long-term clinical outcome of 56 patients with biopsy-proven lupus nephritis, followed at a single center. Lupus 1992; 1: 97-103.16.Jacobsen S., Starklint H., Petersen J. et al. Prognostic value of renal biopsy and clinical variables in patients with lupus nephritis and normal serum creatinine. Scand J. Rheumatol. 1999; 28: 288-299.17.Valery A., Radhakrishnah I., Estes D. et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin. Nephrol. 1994; 42: 71-78.18.Font J., Ramos-Casals M., Cerevra R. et al. Cardiovascular risk factors and the long-term outcome of lupus nephritis. Quart. J. Med. 2001; 94: 19-26.19.Decombes E., Droz D., Dronet L. et al. Renal vascular lesions in lupus nephritis. Medicine (Baltimore) 1997; 76: 355-368.20.Kashagarian M. The role of kidney biopsy in the treatment of lupus nephritis. Ren. Fail. 1996; 18: 765-773.21.Ferrari P., Frey F. J. Immunosupressive therapy of glomerulonephritis controlled studies. Titer. Umsch. 1993; 50: 119- 129.22.McGown J. R., Ellis S., Griffits M. et al. Retrospective analysis of outcome in a cohort of patients with lupus nephritis, treated between 1977 and 1999. Rheumatology 2002; 41: 981-987.23.Shen K., Yn Y., Tang Z. et al. The prognosis biopsy-proven lupus-nephritis in Chinese patients: long-term follow-up of 86 cases. Chin. Med. J. 1997; 110: 502-507.24.Pasquali S., Banfi G., Zucchelli A. et al. Lupus membranous nephropathy: long-term outcome. Clin. Nephrol. 1993; 39: 175-182.25.Martins L., Rocha G., Rodriges A. et al. Lupus nephritis: a retrospective review of 78 cases from a single center. Ibid. 2002- 57: 114-119.26.Мок С. С., Но С. Т., Chan К. W. et al. Outcome and prognosis indicators of diffuse proliferative lupus glomerulonephritis, treated with sequential oral cyclophosphamide and azatioprine. Arthr. and Rheum. 2002; 46: 1003-1013.27.Gladman D. D. Prognosis of systemic lupus erythematosus and factors that affect it. Curr. Opin. Rheumatol. 1991; 5: 789- 796.28.Appel G. В., Valeri A. The course and treatment of lupus nephritis. Ann. Rev. Med. 1994; 45: 525-537.29.Mosca M., Neri R., Gianessi S. et al. Therapy with pulse methylprednisolone and short-corse pulse cyclophosphamide for diffuse proliferative glomerulonephritis. Lupus 2001; 10: 253- 257.30.Doria A., Piccoli A., Vesco P. et al. Therapy of lupus nephritis: A two-year prospective study. Ann. Med. Interne 1994; 145: 307-311.31.Golan E., Weintal I., Bernheim J. et al. Long-term follow-up of the treatment of diffuse ptoliferative glomerulonephritis in patients with systemic lupus erythematosus. Harefuah 2002; 141: 324-328, 412.32.Bansal V. K., Beto J. A. Treatment of lupus nephritis: A meta- analysis of clinical trials. Am. J. Kidney Dis. 1997; 29: 193- 199.33.Boumpas D. Т., Austin H. A., Vaughn E. M. et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-745.34.Lehman T. J. Current concepts in immunosupressive drug therapy of systemic lupus erythematosus. J. Rheumatol. 1992; 19 (suppl. 33): 20-22.35.Mclnnes P. M., Schuttinga J., Sanslone W. K. et al. The economic impact of treatment of severe lupus nephritis with prednison and intravenous cyclophosphamide. Arthr. and Rheum. 1994; 37: 1000-1006.36.Cohen M. G., Li E. K., Lui S. F. et al. Intravenous cyclophosphamide in Chinese patients with diffuse proliferative lupus nephritis. Austral. N. Z. J. Med. 1992; 22: 740.37.Korbet S. M., Lewis E. J., Schwartz M. M. et al. Factors predictive of outcome in severe lupus nephritis. Am. J. Kidney Dis. 2000; 35:901-914.38.Najafi С. С., Korbet S. M., Lewis E. J. et a!. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulohephritis. Kidney Int. 2001; 59: 2156-2163.39.Colon P. J., Fisher C. A., Levesque M. C. et al. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis. Clin. Nephrol. 1996; 46:170-175.40.Xie S. K., Feng S. F., Fu H. Long-term follow-up of patients with systemic lupus erythematosus. J. Dermatol. 1998; 25: 367-373.41.Yeung С. К., Wong W. S., Ng M. T. et al. Crescentic lupus glomerulonephritis. Clin. Nephrol. 1984; 21: 251-258.42.Monova D., Argirova Т., Monov S. Antiribosomal P antibodies in patients with lupus glomerulonephritis. Clin. Nephrol. 2001: 55: 425-426.43.Furie R. A., Cash J. M., Cronin M. E. et al. Treatment of systemic lupus erythematosus with LJP 394. J. Rheumatol. 2001; 28: 257-265.44.Takahashi H., Moroi M. Antibody against platelet membrane glicoprotein VI in a patient with systemic lupus erythmatosus.Am. J. Hematol. 2001; 67: 262-267.45.Сперанский A.M., Насонова В. А., Рязанцева Т. А. и др. Сравнительное исследование активности иммуноглобулина G и лечебных препаратов нормального иммуноглобулина человека у больных с системной красной волчанкой, ревматоидным артритом и здоровых лиц. Ревматология 1991; 1:22-24.46.Hayslett J. P., Esdaile J. M. Response to therapy as a predictor of outcome in lupus. Clin. Invest. Med. 1992; 15: 145.47.Abraham M. A., Korula A., Jayakrishnan K. et al. Prognostic factors in diffuse proliferative lupus nephritis. J. Assoc. Physicians India 1999; 47: 862-865.48.De Bandt M., Goycochea M. V., Meyer O. et al. Traitment du lupus erythemateux aigu dissimine par cyclophosphamide. Ann. Med. Interne 1994; 145: 175-187.49.Paton N. I. J., Cheong 1. K. S., Kong N. С. Т. et al. Risk factors for infections in Malaysian patients with SLE. Quart. J. Med. 1996; 89: 531-538